[{"indications": "Indications\u00a0type 2 diabetes mellitus", "name": "GLICLAZIDE Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.1 Drugs used in diabetes", "6.1.2 Antidiabetic drugs", "6.1.2.1 Sulfonylureas", "GLICLAZIDE", "Modified release"], "cautions": "Cautions\u00a0\n(From 6.1.2.1 Sulfonylureas: British National Formulary)\nCautions\u00a0Sulfonylureas can encourage weight gain and should be prescribed only if poor control and symptoms persist despite adequate attempts at dieting; metformin (section 6.1.2.2) is considered the drug of choice in obese patients. Caution is needed in the elderly and in patients with G6PD deficiency (section 9.1.5).; interactions: Appendix 1 (antidiabetics)", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106128.htm", "doses": ["Initially, 40\u201380\u00a0mg daily, adjusted according to response;\r\nup to 160\u00a0mg as a single dose, with breakfast; higher doses divided;\r\nmax. 320\u00a0mg daily", "Name[Diamicron\u00ae MR (Servier) ] Tablets, m/r, gliclazide 30\u00a0mg,\r\nnet price 28-tab pack = \u00a32.81, 56-tab pack = \u00a35.62. \r\n    Label:\r\n    25Dose\u00a0adult initially\r\n30\u00a0mg daily with breakfast, adjusted according to response every 4\r\nweeks (after 2 weeks if no decrease in blood glucose); max. 120\u00a0mg\r\ndailyNote\u00a0Diamicron\u00ae MR 30\u00a0mg may\r\nbe considered to be approximately equivalent in therapeutic effect\r\nto standard formulation Diamicron\u00ae 80\u00a0mg "], "pregnancy": "Pregnancy\u00a0\n(From 6.1.2.1 Sulfonylureas: British National Formulary)\nPregnancy\u00a0The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia; however, glibenclamide can be used during the second and third trimesters of pregnancy in women with gestational diabetes, see section 6.1.2."}, {"indications": "Indications\u00a0type 2 diabetes mellitus", "name": "GLICLAZIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.1 Drugs used in diabetes", "6.1.2 Antidiabetic drugs", "6.1.2.1 Sulfonylureas", "GLICLAZIDE"], "cautions": "Cautions\u00a0\n(From 6.1.2.1 Sulfonylureas: British National Formulary)\nCautions\u00a0Sulfonylureas can encourage weight gain and should be prescribed only if poor control and symptoms persist despite adequate attempts at dieting; metformin (section 6.1.2.2) is considered the drug of choice in obese patients. Caution is needed in the elderly and in patients with G6PD deficiency (section 9.1.5).; interactions: Appendix 1 (antidiabetics)", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106127.htm", "doses": ["Initially, 40\u201380\u00a0mg daily, adjusted according to response;\r\nup to 160\u00a0mg as a single dose, with breakfast; higher doses divided;\r\nmax. 320\u00a0mg daily"], "pregnancy": "Pregnancy\u00a0\n(From 6.1.2.1 Sulfonylureas: British National Formulary)\nPregnancy\u00a0The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia; however, glibenclamide can be used during the second and third trimesters of pregnancy in women with gestational diabetes, see section 6.1.2."}]